134 related articles for article (PubMed ID: 11027463)
1. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
Inuzuka K; Ogata Y; Nagase H; Shirouzu K
J Surg Res; 2000 Oct; 93(2):211-8. PubMed ID: 11027463
[TBL] [Abstract][Full Text] [Related]
2. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
[TBL] [Abstract][Full Text] [Related]
3. [Significance in gene expression of matrix metalloproteinase-9, urokinase-type plasminogen activator and tissue inhibitor of metalloproteinase for metastases of gastric and/or colo-rectal cancer].
Koumura H; Sugiyama Y; Kunieda K; Saji S
Gan To Kagaku Ryoho; 1997 Jul; 24 Suppl 2():324-31. PubMed ID: 9263524
[TBL] [Abstract][Full Text] [Related]
4. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.
Tan X; Egami H; Nozawa F; Abe M; Baba H
Int J Oncol; 2006 Feb; 28(2):369-74. PubMed ID: 16391791
[TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.
Harvey SR; Hurd TC; Markus G; Martinick MI; Penetrante RM; Tan D; Venkataraman P; DeSouza N; Sait SN; Driscoll DL; Gibbs JF
Clin Cancer Res; 2003 Oct; 9(13):4935-43. PubMed ID: 14581368
[TBL] [Abstract][Full Text] [Related]
8. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
[TBL] [Abstract][Full Text] [Related]
9. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
Yang SF; Hsieh YS; Lin CL; Hsu NY; Chiou HL; Chou FP; Chu SC
Clin Chim Acta; 2005 Apr; 354(1-2):91-9. PubMed ID: 15748604
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
12. Expression and activation of proteases in co-cultures.
Paduch R; Kandefer-Szerszeń M
Exp Toxicol Pathol; 2011 Jan; 63(1-2):79-87. PubMed ID: 19836935
[TBL] [Abstract][Full Text] [Related]
13. PTHrP [67-86] regulates the expression of stress proteins in breast cancer cells inducing modifications in urokinase-plasminogen activator and MMP-1 expression.
Luparello C; Sirchia R; Pupello D
J Cell Sci; 2003 Jun; 116(Pt 12):2421-30. PubMed ID: 12724357
[TBL] [Abstract][Full Text] [Related]
14. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
[TBL] [Abstract][Full Text] [Related]
15. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
16. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
17. Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma.
Yamamoto H; Vinitketkumnuen A; Adachi Y; Taniguchi H; Hirata T; Miyamoto N; Nosho K; Imsumran A; Fujita M; Hosokawa M; Hinoda Y; Imai K
Carcinogenesis; 2004 Dec; 25(12):2353-60. PubMed ID: 15333466
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells.
Pei XH; Nakanishi Y; Takayama K; Bai F; Hara N
Br J Cancer; 1999 Jan; 79(1):40-6. PubMed ID: 10408691
[TBL] [Abstract][Full Text] [Related]
19. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles.
Graves LE; Ariztia EV; Navari JR; Matzel HJ; Stack MS; Fishman DA
Cancer Res; 2004 Oct; 64(19):7045-9. PubMed ID: 15466198
[TBL] [Abstract][Full Text] [Related]
20. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
